These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36708129)

  • 21. ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption.
    Vilar-Gomez E; Sookoian S; Pirola CJ; Liang T; Gawrieh S; Cummings O; Liu W; Chalasani NP
    Gastroenterology; 2020 Sep; 159(3):929-943. PubMed ID: 32454036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).
    Dunn W; Sanyal AJ; Brunt EM; Unalp-Arida A; Donohue M; McCullough AJ; Schwimmer JB
    J Hepatol; 2012 Aug; 57(2):384-91. PubMed ID: 22521357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies.
    Hayat U; Siddiqui AA; Okut H; Afroz S; Tasleem S; Haris A
    Ann Hepatol; 2021; 20():100254. PubMed ID: 32920163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies.
    Ebadi M; Ip S; Bhanji RA; Montano-Loza AJ
    Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease.
    Zheng T; Wang X; Kamili K; Luo C; Hu Y; Wang D; Wang B; Gao P; Tian G
    Scand J Gastroenterol; 2024 Apr; 59(4):480-488. PubMed ID: 38179969
    [No Abstract]   [Full Text] [Related]  

  • 27. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
    Chen J; Song S; Li X; Bian D; Wu X
    Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
    Stine JG; Wentworth BJ; Zimmet A; Rinella ME; Loomba R; Caldwell SH; Argo CK
    Aliment Pharmacol Ther; 2018 Oct; 48(7):696-703. PubMed ID: 30136293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease.
    Ferri S; Stefanini B; Mulazzani L; Alvisi M; Tovoli F; Leoni S; Muratori L; Lotti T; Granito A; Bolondi L; Piscaglia F
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modifiers of Liver-Related Manifestation in the Course of NAFLD.
    Nasr P; Blomdahl J; Kechagias S; Ekstedt M
    Curr Pharm Des; 2020; 26(10):1062-1078. PubMed ID: 32156227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis.
    Jarvis H; O'Keefe H; Craig D; Stow D; Hanratty B; Anstee QM
    BMJ Open; 2022 Jan; 12(1):e049767. PubMed ID: 34983755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.
    Tovo CV; de Mattos AZ; Coral GP; Sartori GDP; Nogueira LV; Both GT; Villela-Nogueira CA; de Mattos AA
    World J Gastroenterol; 2023 Jan; 29(2):343-356. PubMed ID: 36687125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease.
    Patel PJ; Smith D; Connor JP; Horsfall LU; Hayward KL; Hossain F; Williams S; Johnson T; Stuart KA; Brown NN; Saad N; Clouston AD; Irvine KM; Russell AW; Valery PC; Powell EE
    Can J Gastroenterol Hepatol; 2017; 2017():7927685. PubMed ID: 29226116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
    Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.